My Treatment Approach: Translating Evidence to Clinical Practice in Advanced RCC   - Episode 3

Ongoing Clinical Trials in the front-line setting of advanced non-clear cell RCC

,

Moshe Ornstein, MD, presents an overview of the current front-line treatment options for advanced non-clear cell renal cell carcinoma, focusing on the PAPMET regimen and the promising results from the Phase 2 study investigating the combination of nivolumab and cabozantinib.

  1. Please review some of the other therapies for the treatment of advanced non-clear cell RCC in the front-line setting:
    1. PAPMET (Tripathi A et al. JCO 2023)
    2. Phase 2 study (Nivo + Cabo): (Lee CH, et al. ASCO 2023. Abstract 4537)